How the FDA will spend your fees

Curious how the FDA might spend its PDUFA fees? A new five-year plan shows that FDA will plow the money into post-marketing safety to meet its commitments under the new law passed last fall. The agency would spend the to boost the number of employees looking at new scientific approaches to drug safety, improving adverse event detection and prevention programs, and cutting back on medication errors. Plus, it would invest millions in epidemiology "best practices" and data acquisition. Want more detail? Check out the plan itself on the FDA website.

- see the plan
- check out the story at FDA News

Related Articles:
FDA aims to hire 1,300 by October
FDA: Drugmakers responsible for safety
House passes PDUFA: bill heads to Senate
Panel: Give FDA power to recall

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.